EP Patent

EP1121104B1 — New controlled release oral formulations for rivastigmine

Assigned to Novartis Pharma GmbH · Expires 2005-01-12 · 21y expired

What this patent protects

Pharmaceutical composition capable of releasing a therapeutically effective dose of active agent, e.g., rivastigamine, in a time-controlled manner.

USPTO Abstract

Pharmaceutical composition capable of releasing a therapeutically effective dose of active agent, e.g., rivastigamine, in a time-controlled manner.

Drugs covered by this patent

doxycycline-hyclate (DOXYCYCLINE HYCLATE)

Patent Metadata

Patent number: EP1121104B1
Jurisdiction: EP
Classification: —
Expires: 2005-01-12
Drug substance claim: No
Drug product claim: No
Assignee: Novartis Pharma GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.